Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 408,436
  • Shares Outstanding, K 59,108
  • Annual Sales, $ 216,110 K
  • Annual Income, $ -220,470 K
  • EBIT $ -144 M
  • EBITDA $ -134 M
  • 60-Month Beta 0.55
  • Price/Sales 1.95
  • Price/Cash Flow N/A
  • Price/Book 1.29

Options Overview Details

View History
  • Implied Volatility 221.39% (+63.22%)
  • Historical Volatility 131.21%
  • IV Percentile 98%
  • IV Rank 63.53%
  • IV High 332.52% on 11/14/25
  • IV Low 27.75% on 09/04/25
  • Expected Move (DTE 18) 0.98 (14.72%)
  • Put/Call Vol Ratio 2.17
  • Today's Volume 152
  • Volume Avg (30-Day) 1,859
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 17,802
  • Open Int (30-Day) 36,770
  • Expected Range 5.66 to 7.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.53
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.57
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -6.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.61 +0.08%
on 03/30/26
9.94 -33.40%
on 03/10/26
-2.29 (-25.70%)
since 02/27/26
3-Month
5.73 +15.53%
on 02/20/26
9.94 -33.40%
on 03/10/26
-0.42 (-5.97%)
since 12/26/25
52-Week
3.81 +73.79%
on 05/15/25
9.94 -33.40%
on 03/10/26
+1.93 (+41.15%)
since 03/28/25

Most Recent Stories

More News
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

WASHINGTON , March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing,...

VNDA : 6.62 (-4.20%)
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

WASHINGTON , March 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for...

VNDA : 6.62 (-4.20%)
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

WASHINGTON , Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami...

VNDA : 6.62 (-4.20%)
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

WASHINGTON , Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics...

VNDA : 6.62 (-4.20%)
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

WASHINGTON , Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets,...

VNDA : 6.62 (-4.20%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are...

VNDA : 6.62 (-4.20%)
Vanda: Q4 Earnings Snapshot

Vanda: Q4 Earnings Snapshot

VNDA : 6.62 (-4.20%)
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

WASHINGTON , Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December...

VNDA : 6.62 (-4.20%)
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Conference Call and Webcast to Follow

VNDA : 6.62 (-4.20%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA).  Such investors...

VNDA : 6.62 (-4.20%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 7.49
2nd Resistance Point 7.37
1st Resistance Point 7.14
Last Price 6.62
1st Support Level 6.79
2nd Support Level 6.67
3rd Support Level 6.44

See More

52-Week High 9.94
Fibonacci 61.8% 7.60
Fibonacci 50% 6.87
Last Price 6.62
Fibonacci 38.2% 6.15
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.